Navigation Links
Reprogramming cells to fight diabetes
Date:2/22/2013

PHILADELPHIA For years researchers have been searching for a way to treat diabetics by reactivating their insulin-producing beta cells, with limited success. The "reprogramming" of related alpha cells into beta cells may one day offer a novel and complementary approach for treating type 2 diabetes. Treating human and mouse cells with compounds that modify cell nuclear material called chromatin induced the expression of beta cell genes in alpha cells, according to a new study that appears online in the Journal of Clinical Investigation.

"This would be a win-win situation for diabetics - they would have more insulin-producing beta cells and there would be fewer glucagon-producing alpha cells," says lead author Klaus H. Kaestner, Ph.D., professor of Genetics and member of the Institute of Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania. Type 2 diabetics not only lack insulin, but they also produce too much glucagon.

Both type 1 and type 2 diabetes are caused by insufficient numbers of insulin-producing beta cells. In theory, transplantation of healthy beta cells for type 1 diabetics in combination with immunosuppression to control autoimmunity - should halt the disease, yet researchers have not yet been able to generate these cells in the lab at high efficiency, whether from embryonic stem cells or by reprogramming mature cell types.

Alpha cells are another type of endocrine cell in the pancreas. They are responsible for synthesizing and secreting the peptide hormone glucagon, which elevates glucose levels in the blood.

"We treated human islet cells with a chemical that inhibits a protein that puts methyl chemical groups on histones, which - among many other effects - leads to removal of some histone modifications that affect gene expression," says Kaestner. "We then found a high frequency of alpha cells that expressed beta-cell markers, and even produced some insulin, after
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. A relationship between cancer genes and the reprogramming gene SOX2 discovered
2. New drug prevents spread of human prostate cancer cells
3. Tiny hitchhikers attack cancer cells
4. To prevent leukemias dreaded return, go for the stem cells
5. Scientists identify major source of cells defense against oxidative stress
6. Therapy exploits addiction of leukemia cells
7. IBN discovers human neural stem cells with tumor targeting ability
8. Leukaemia cells have a remembrance of things past
9. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
10. Research yields new clues to how brain cancer cells migrate and invade
11. Presence of fetal cells in women lowers risk of breast cancer but raises risk of colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reprogramming cells to fight diabetes
(Date:4/27/2015)... According to a recent report from ... chronic back pain, TMJ disorders are the second ... disability. In addition, the report revealed that TMJ disorders ... costing an estimated 4 billion dollars annually. , These ... seemingly unrelated symptoms such as headaches, neck pain, tenderness ...
(Date:4/27/2015)... Thanks to a $7.5 million grant from ... institutions, including American University, will operate in a new ... behavioral research aimed at ending the AIDS epidemic. , ... HIV or AIDS, according to the latest statistics. At ... over the age of 13 was living with HIV, ...
(Date:4/27/2015)... April 27, 2015 Doctors on Liens ... on a lien basis for over twenty years. So when ... the best doctor in the Fresno area , Doctors ... DC and his team of medical specialists. With a ... massage therapist, Dilanchian Chiropractic is now helping more ...
(Date:4/27/2015)... Church, VA (PRWEB) April 27, 2015 ... Integrity Issues Within Your Operations or Your Partners/Suppliers, **FDAnews ... p.m. EDT, http://www.fdanews.com/DataIntegrity , Data integrity issues ... the last few years., Uncovering data integrity issues within ... once data integrity issues come to light, remediating them ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 FMC Corporation’s ... exhibit its wide range of market leading ingredients and ... 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects to ... countries showcasing the latest research in such areas as ... , FMC Health and Nutrition’s booth will feature ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... ... some people have questioned if the HCG diet can be harmful. Dr Robert True addresses ... , ... Dr. Robert sees patients on a daily basis that he helps lose weight through his ...
... ... BtoB companies seeking a proven approach for lead cultivation with social media. , ... Portland, OR (PRWEB) March 24, 2010 -- ... Five Ways to Leads: How BtoBs Should Use Social Media , a complimentary Webinar event ...
... This release is available in Spanish . ... same area as the original tumour remains the strongest, independent ... who have been free of disease for a very long ... European Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, ...
... available in Spanish . Barcelona, Spain: ... goal in survival with new treatment should be to prolong ... might expect from using current best therapies, a researcher will ... today (Wednesday). This finding contrasts with doctors, perception that an ...
... the Barcelona Public Health Agency has revealed those sections of ... published in the journal Respiratory Research , shows that ... aged over 50 or infected with HIV. "Some patients ... of six months), resulting in a danger of them infecting ...
... the death of a loved one can provide much-needed consolation ... study in the April issue of the Journal of ... a relative to cancer took part in the study. Participants ... widows, widowers, daughters and sisters. Nine chose foot massage, eight ...
Cached Medicine News:Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Webinar Shares Proven Social Media Approach to BtoB Lead Generation 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older people and those with HIV are more vulnerable to tuberculosis 2Health News:Hand and feet massages provide consolation for bereaved relatives 2
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: